| 190.85 -0.05 (-0.03%) | 10-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 227.05  |
1-year : | 265.2 |
| Resists | First : | 194.39 |
Second : | 227.05 |
| Pivot price | 186.14 |
|||
| Supports | First : | 181.37 |
Second : | 173.33 |
| MAs | MA(5) : | 190.64 |
MA(20) : | 183.52 |
| MA(100) : | 168.49 |
MA(250) : | 160.29 |
|
| MACD | MACD : | 3.9 |
Signal : | 3.4 |
| %K %D | K(14,3) : | 88.7 |
D(3) : | 92.2 |
| RSI | RSI(14): 75.9 |
|||
| 52-week | High : | 194.39 | Low : | 140.67 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ JNJ ] has closed below upper band by 25.4%. Bollinger Bands are 81.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 194.69 - 195.67 | 195.67 - 196.47 |
| Low: | 183.67 - 184.68 | 184.68 - 185.51 |
| Close: | 189.34 - 190.96 | 190.96 - 192.29 |
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Tue, 14 Oct 2025
Johnson says ‘I don’t have anything to negotiate’ as US shutdown drags on - The Guardian
Tue, 14 Oct 2025
House Speaker Johnson says he won’t negotiate with Democrats on the shutdown - CNN
Tue, 14 Oct 2025
Arizona attorney general threatens legal action against Mike Johnson for failing to seat Adelita Grijalva - Politico
Tue, 14 Oct 2025
Ravens release veteran CJGJ 1 week after signing - ESPN
Tue, 14 Oct 2025
NFL news roundup: Ravens release DB C.J. Gardner-Johnson prom practice squad - NFL.com
Tue, 14 Oct 2025
Speaker Johnson embraces Freedom Caucus tactics in shutdown fight - The Hill
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 2,410 (M) |
| Shares Float | 2,400 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 74.4 (%) |
| Shares Short | 18,180 (K) |
| Shares Short P.Month | 18,840 (K) |
| EPS | 9.35 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 32.59 |
| Profit Margin | 25 % |
| Operating Margin | 28.9 % |
| Return on Assets (ttm) | 7.6 % |
| Return on Equity (ttm) | 30.2 % |
| Qtrly Rev. Growth | 5.8 % |
| Gross Profit (p.s.) | 25.72 |
| Sales Per Share | 37.6 |
| EBITDA (p.s.) | 12.55 |
| Qtrly Earnings Growth | 18.7 % |
| Operating Cash Flow | 23,030 (M) |
| Levered Free Cash Flow | 11,080 (M) |
| PE Ratio | 20.41 |
| PEG Ratio | 0 |
| Price to Book value | 5.85 |
| Price to Sales | 5.07 |
| Price to Cash Flow | 19.97 |
| Dividend | 1.29 |
| Forward Dividend | 0 |
| Dividend Yield | 0.6% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|